RNA vaccines articles within Nature

Featured

  • Article
    | Open Access

    Convergent mutations in hot spots of the spike proteins of currently circulating SARS-CoV-2 Omicron variants increase the binding affinity for the host receptor and promote more efficient fusion with host cell membranes.

    • Amin Addetia
    • , Luca Piccoli
    •  & David Veesler

  • Article
    | Open Access

    An algorithm based on concepts established in computational linguistics enables rapid principled design of mRNA vaccines optimizing both structural stability and codon usage, resulting in improved half-life, protein expression and immune responses.

    • He Zhang
    • , Liang Zhang
    •  & Liang Huang

  • Article |

    COVID-19 booster immunizations aimed at spike protein from new SARS-CoV-2 variants induce robust germinal centre B cell responses against the original spike protein, as well as de novo B cell responses against the variant spike protein.

    • Wafaa B. Alsoussi
    • , Sameer Kumar Malladi
    •  & Ali H. Ellebedy

  • Article
    | Open Access

    Pre-existing high-affinity antibodies alter germinal centre and memory B cell selection by lowering the activation threshold for B cells and through direct masking of their cognate epitopes, thereby permitting a diverse set of abundant lower-affinity clones targeting alternate epitopes to participate in the immune response.

    • Dennis Schaefer-Babajew
    • , Zijun Wang
    •  & Michel C. Nussenzweig

  • Article |

    Sera from unvaccinated, vaccinated, and previously infected and vaccinated individuals show reduced neutralizing and spike protein-binding activity towards the Omicron (B.1.1.529) variant of SARS-CoV-2 compared to other variants.

    • Juan Manuel Carreño
    • , Hala Alshammary
    •  & Florian Krammer

  • Article
    | Open Access

    Longitudinal analyses of SARS-CoV-2 mRNA vaccine-elicited epitope-specific CD8+ T cell responses shows that CD8+ T cells are rapidly induced after prime vaccination and stably maintained after boost vaccination.

    • Valerie Oberhardt
    • , Hendrik Luxenburger
    •  & Maike Hofmann

  • Article |

    Profiling the immune responses of 56 volunteers vaccinated with BNT162b2 reveals how this mRNA vaccine primes the innate immune system to mount a potent response to SARS-CoV-2 after booster immunization.

    • Prabhu S. Arunachalam
    • , Madeleine K. D. Scott
    •  & Bali Pulendran

  • Article |

    Analysis of antigen-specific B cells in lymph nodes of individuals vaccinated with BNT162b2 reveals lasting germinal centre responses, explaining the robust humoral immunity induced by SARS-CoV-2 mRNA-based vaccines.

    • Jackson S. Turner
    • , Jane A. O’Halloran
    •  & Ali H. Ellebedy

  • Article |

    Immunization of macaques with nanoparticle-conjugated receptor-binding domain of SARS-CoV-2 adjuvanted with 3M-052 and alum results in cross-neutralizing antibodies against bat coronaviruses, SARS-CoV and SARS-CoV-2 variants, and may provide a platform for developing pan-coronavirus vaccines.

    • Kevin O. Saunders
    • , Esther Lee
    •  & Barton F. Haynes

  • Article |

    BNT162b1 and BNT162b2 are two candidate mRNA vaccines against COVID-19 that elicit high virus-entry inhibition titres in mice, elicit high virus-neutralizing titres in rhesus macaques and protect macaques from SARS-CoV-2 challenge.

    • Annette B. Vogel
    • , Isis Kanevsky
    •  & Ugur Sahin

  • Article |

    mRNA-1273, an mRNA vaccine that encodes a stabilized prefusion-state severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, elicits robust immune responses and protects mice against replication of SARS-CoV-2 in the upper and lower airways.

    • Kizzmekia S. Corbett
    • , Darin K. Edwards
    •  & Barney S. Graham

  • Article |

    Results of an exploratory interim analysis from a phase I trial show that an RNA vaccine targeted towards four melanoma-associated antigens produces durable objective responses in patients with melanoma that are accompanied by strong CD4+ and CD8+ T-cell immunity.

    • Ugur Sahin
    • , Petra Oehm
    •  & Özlem Türeci

  • Letter |

    A single, low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA encoding the pre-membrane and envelope glycoproteins of Zika virus protects both mice and rhesus macaques against infection and elicits rapid and long-lasting neutralizing antibody responses.

    • Norbert Pardi
    • , Michael J. Hogan
    •  & Drew Weissman

  • Letter |

    The development of a nanoparticle RNA vaccine is reported that preferentially targets dendritic cells after systemic administration, and is shown to provide durable interferon-α-dependent antigen-specific immunity in mouse tumour models; initial results in advanced melanoma patients indicate potential efficacy in humans.

    • Lena M. Kranz
    • , Mustafa Diken
    •  & Ugur Sahin

Browse broader subjects

Browse RNA vaccines across other nature.com journals